These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2668648)

  • 1. Differentiation induction therapy of myelodysplastic syndromes.
    Hassan HT; Rees J
    Leuk Res; 1989; 13(7):633-7. PubMed ID: 2668648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly.
    Pinto A; Zagonel V; Attadia V; Bullian PL; Gattei V; Carbone A; Monfardini S; Colombatti A
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():28-32. PubMed ID: 2483349
    [No Abstract]   [Full Text] [Related]  

  • 3. Differentiation in acute myeloid leukemia and myelodysplastic disorders. Is differentiation-induction therapy possible?
    Januszewicz EH; Firkin FC
    Aust N Z J Med; 1988 Aug; 18(5):705-11. PubMed ID: 3072952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic syndromes (preleukemia).
    Koeffler HP
    Semin Hematol; 1986 Oct; 23(4):284-99. PubMed ID: 3535083
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of treatment with 13-cis-retinoic acid and ara-C on the hematopoietic stem cells of patients with myelodysplastic syndromes].
    García Marco J; Miguel Sosa A; García Conde J; Miguel García A; Arbona C; Escrig V; Benet I; Navarro I; Ruiz A; Carbonell F
    Sangre (Barc); 1994 Aug; 39(4):241-4. PubMed ID: 7985051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation induction in myelodysplasia and acute myeloid leukaemia: use of synergistic drug combinations.
    Francis GE; Mufti GJ; Knowles SM; Berney JJ; Guimaraes JE; Secker-Walker LM; Hamblin TJ
    Leuk Res; 1987; 11(11):971-7. PubMed ID: 3480401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Present results of the treatment of myelodysplastic syndromes with low-dose cytosine arabinoside. Preliminary results of a cooperative protocol (38 patients) and review of the literature.
    Chomienne C; Najean Y; Degos L; Thomas G; Baumelou E; Calvo F; Casassus P; Ciccone F; Fenaux P; Gris JC
    Acta Haematol; 1987; 78 Suppl 1():109-15. PubMed ID: 3124432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.
    Rowinsky EK; Donehower RC; Spivak JL; Burke PJ; Griffin CA; Jones RJ
    J Natl Cancer Inst; 1990 Dec; 82(24):1926-31. PubMed ID: 2250314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The myelodysplastic syndromes: current approaches to therapy.
    Cheson BD
    Ann Intern Med; 1990 Jun; 112(12):932-41. PubMed ID: 2187393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrasting patterns of neoplastic cell behaviour in long-term culture of bone marrow from patients with acute leukaemia and myelodysplastic disorders. A survey of responses in 31 cases with cytogenetic determination of neoplastic status of cultured cells in 17 studies.
    Firkin FC; Birner R; Russell SH; Garson OM
    Br J Haematol; 1990 Aug; 75(4):476-84. PubMed ID: 2206999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preleukaemia and myelodysplastic syndromes today.
    Jacobs A
    Recenti Prog Med; 1989 Oct; 80(10):501-7. PubMed ID: 2690216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary myelodysplastic syndromes of dogs: a report of 12 cases.
    Weiss DJ; Smith SA
    J Vet Intern Med; 2000; 14(5):491-4. PubMed ID: 11012110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro growth and differentiation of marrow cells from myelodysplastic patients in the presence of a retinoidal benzoic acid derivative.
    Fabian I; Shvartzmayer S; Nagler A
    Leuk Res; 1987; 11(7):635-40. PubMed ID: 3613648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro.
    Huang XK; Meyer P; Li B; Raza A; Preisler HD
    Leuk Lymphoma; 2003 Jan; 44(1):157-64. PubMed ID: 12691158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating agents in the treatment of leukemia and myelodysplastic syndromes.
    Degos L
    Leuk Res; 1990; 14(8):731-3. PubMed ID: 2201824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Round table: Differentiation of human malignant lymphoid and myeloid cells].
    Nouv Rev Fr Hematol (1978); 1987; 29(2):129-39. PubMed ID: 3475675
    [No Abstract]   [Full Text] [Related]  

  • 17. [Secondary dysmyelopoiesis in patients with myelodysplastic syndromes].
    Dvirnyk VN; Kokhno AV; Parovichnikova EN
    Ter Arkh; 2014; 86(7):97-103. PubMed ID: 25314785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation therapy for myelodysplastic syndrome.
    Hofmann WK; Koeffler HP
    Clin Cancer Res; 2002 Apr; 8(4):939-41. PubMed ID: 11948096
    [No Abstract]   [Full Text] [Related]  

  • 19. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors.
    Merchav S; Wagemaker G; Souza LM; Tatarsky I
    Leukemia; 1991 Apr; 5(4):340-6. PubMed ID: 1709245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow colony-forming unit assay in cats with naturally occurring myelodysplastic syndromes.
    Nagashima N; Hisasue M; Higashi K; Kano R; Tsujimoto H; Hasegawa A
    Int J Hematol; 2001 Jun; 73(4):453-456. PubMed ID: 11503958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.